Advertisement

DARU Journal of Pharmaceutical Sciences

, Volume 26, Issue 2, pp 91–92 | Cite as

Metal and bacterial contamination of illicit drugs

  • Jonathan Schimmel
  • Samaneh Nakhaee
  • Omid Mehrpour
Letter to the Editor
  • 28 Downloads

Dear Editor-in-Chief

We read with great interest the article by Aghababaei et al. [1]. It is a valuable study that furthers the significant base of literature on contamination of illicit drugs. We wish to comment on several aspects of the study, and to evaluate the methodology and findings in the context of prior work.

The reasons for intentional drug contamination are diverse, including bulking or enhancement of drug effect. Unintentional contamination may follow manufacturing impurities or storage effects. Occasionally, the reasons for contamination are unclear, such as the recent outbreak of brodifacoum tainted synthetic cannabinoids in the United States [2].

Metal contamination of illicit drugs has been understudied, in part because many analyses have used techniques intended to detect volatile compounds, or utilized liquid chromatographic techniques without specifically evaluating for metals. Prior reports have investigated metals in methamphetamine, cannabis, heroin, opium, and...

References

  1. 1.
    Aghababaei R, et al. Occurrence of bacterial and toxic metals contamination in illegal opioid-like drugs in Iran: a significant health challenge in drug abusers. DARU J Pharm Sci. 2018;1.Google Scholar
  2. 2.
    Moritz E, Austin C, Wahl M, DesLauriers C, Navon L, Walblay K, et al. Notes from the field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic cannabinoids - Illinois, March–April 2018. MMWR Morb Mortal Wkly Rep. 2018;67:607–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Burton BT. Heavy metal and organic contaminants associated with illicit methamphetamine production. NIDA Res Monogr. 1991;115:47–59.PubMedGoogle Scholar
  4. 4.
    Infante F, Dominguez E, Trujillo D, Luna A. Metal contamination in illicit samples of heroin. J Forensic Sci. 1999;44(1):110–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Exley C, et al. Aluminum in tobacco and cannabis and smoking-related disease. Am J Med. 2006;119(3):276–e9.CrossRefPubMedGoogle Scholar
  6. 6.
    Alinejad S, Aaseth J, Abdollahi M, Hassanian-Moghaddam H, Mehrpour O. Clinical aspects of opium adulterated with lead in Iran: a review. Basic Clin Pharmacol Toxicol. 2018;122(1):56–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Nakhaee S, Mehrpour O. Opium addiction as new source of lead poisoning: an emerging epidemic in Iran. EXCLI J. 2018;17:513.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hayatbakhsh MM, Oghabian Z, Conlon E, Nakhaee S, Amirabadizadeh AR, Zahedi MJ, et al. Lead poisoning among opium users in Iran: an emerging health hazard. Subst Abuse Treat Prev Policy. 2017;12(1):43.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ghaemi K, Ghoreishi A, Rabiee N, Alinejad S, Farzaneh E, Zadeh AA, et al. Blood lead levels in asymptomatic opium addict patients; a case control study. Emergency. 2017;5(1):e69.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Domeneh BH, Tavakoli N, Jafari N. Blood lead level in opium dependents and its association with anemia: a cross-sectional study from the capital of Iran. J Res Med Sci. 2014;19:939.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bermejo-Barrera P, et al. Determination of traces of chromium in cocaine and heroin by flameless atomic absorption spectrometry. Talanta. 1996;43(1):77–87.CrossRefPubMedGoogle Scholar
  12. 12.
    Cole C, et al. CUT: a guide to adulterants, bulking agents and other contaminants found in illicit drugs. Liverpool: John Moores University; 2010.Google Scholar
  13. 13.
    Roy S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11:354–65.CrossRefPubMedGoogle Scholar
  15. 15.
    Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golestan cohort study: prospective cohort study of 50 000 adults in Iran. BMJ. 2012;344:e2502.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    McLaren J, et al. Cannabis potency and contamination: a review of the literature. Addiction. 2008;103(7):1100–1109.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Jonathan Schimmel
    • 1
  • Samaneh Nakhaee
    • 2
  • Omid Mehrpour
    • 1
    • 2
  1. 1.Rocky Mountain Poison and Drug CenterDenverUSA
  2. 2.Medical Toxicology and Drug Abuse Research Center (MTDRC)Birjand University of Medical Sciences (BUMS)BirjandIran

Personalised recommendations